One Lambda, which had 2011 revenue of $182m, will become part of Thermo Fisher’s Specialty Diagnostics Segment.
Thermo Fisher Scientific president and chief executive officer Marc Casper said One Lambda’s tests for tissue typing and antibody detection complement the company’s existing immunosuppressant assays, allowing it to offer a menu of tests across the transplant-testing workflow.
"We are excited about this combination and the opportunities it presents to ultimately improve the lives of transplant patients," Casper added.
Based upon the timing of the close, the transaction will have an immaterial impact on its third quarter adjusted EPS, according to Thermo Fisher.